Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy
- PMID: 24487046
- DOI: 10.1016/j.ajo.2014.01.022
Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy
Abstract
Purpose: To compare the efficacy and safety of half-fluence vs half-dose photodynamic therapy (PDT) in chronic central serous chorioretinopathy (CSC).
Design: Multicenter retrospective comparison study.
Methods: Retrospective review of 56 patients affected by chronic CSC, including 28 patients (31 eyes) who received half-fluence PDT and 28 patients (29 eyes) who received half-dose PDT. Best-corrected visual acuity (BCVA), central foveal thickness (CFT), and resolution of subretinal fluid on optical coherence tomography at 1 and 12 months were assessed.
Results: The mean logMAR BCVA improved significantly (P < .001), both in the half-fluence group (from 0.187 [± 0.187] to 0.083 [± 0.164]) and in the half-dose group (from 0.126 [± 0.091] to 0.068 [± 0.091]), at 12 months, without significant difference between the 2 groups. At 1 month a complete resolution of subretinal fluid was observed in 19 half-fluence-treated eyes (61.3%) and in 25 half-dose-treated eyes (86.2%) (P = .04). At 12 months, a complete resolution of subretinal fluid was achieved in 26 half-fluence-treated eyes (83.9%) and 29 half-dose-treated eyes (100%) (P = .0529). Nine eyes (29%) in the half-fluence group and 5 eyes (17.2%) in the half-dose group had at least 1 recurrence of subretinal fluid during the follow-up. Overall there were 15 and 5 recurrences in the half-fluence PDT and half-dose PDT groups, respectively (P = .07). In no eye of either groups was atrophy of the retinal pigment epithelium observed in the area of treatment.
Conclusion: Half-dose PDT induced a more rapid reabsorption of the fluid, a more lasting effect, and equal safety with respect to half-fluence PDT.
Copyright © 2014 Elsevier Inc. All rights reserved.
Comment in
-
Reply: To PMID 24487046.Am J Ophthalmol. 2015 Jan;159(1):205-6. doi: 10.1016/j.ajo.2014.09.037. Am J Ophthalmol. 2015. PMID: 25488642 No abstract available.
-
Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.Am J Ophthalmol. 2015 Jan;159(1):205. doi: 10.1016/j.ajo.2014.09.038. Am J Ophthalmol. 2015. PMID: 25488643 No abstract available.
Similar articles
-
COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.Retina. 2017 Feb;37(2):325-333. doi: 10.1097/IAE.0000000000001138. Retina. 2017. PMID: 27429374 Clinical Trial.
-
Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.Ophthalmology. 2014 Feb;121(2):558-65. doi: 10.1016/j.ophtha.2013.09.024. Epub 2013 Nov 20. Ophthalmology. 2014. PMID: 24268858 Clinical Trial.
-
Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.Graefes Arch Clin Exp Ophthalmol. 2018 Nov;256(11):2027-2034. doi: 10.1007/s00417-018-4086-6. Epub 2018 Aug 10. Graefes Arch Clin Exp Ophthalmol. 2018. PMID: 30097783
-
System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy.Acta Ophthalmol. 2014 Dec;92(8):e594-601. doi: 10.1111/aos.12482. Epub 2014 Jul 13. Acta Ophthalmol. 2014. PMID: 25042260 Review.
-
Comparative efficacy of treatments for chronic central serous chorioretinopathy: A systematic review with network meta-analyses.Acta Ophthalmol. 2023 Mar;101(2):140-159. doi: 10.1111/aos.15263. Epub 2022 Sep 30. Acta Ophthalmol. 2023. PMID: 36178171
Cited by
-
1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy.BMC Ophthalmol. 2015 Jun 30;15:66. doi: 10.1186/s12886-015-0061-8. BMC Ophthalmol. 2015. PMID: 26122636 Free PMC article.
-
Wide-Field Choroidal Thickness Analysis after Half-Fluence Photodynamic Therapy Combined with Intravitreal Aflibercept Injection in Pachychoroid Neovasculopathy.J Clin Med. 2024 Mar 11;13(6):1608. doi: 10.3390/jcm13061608. J Clin Med. 2024. PMID: 38541834 Free PMC article.
-
Oscillatory photodynamic therapy in central serous chorioretinopathy.Graefes Arch Clin Exp Ophthalmol. 2025 May;263(5):1269-1278. doi: 10.1007/s00417-025-06766-0. Epub 2025 Feb 11. Graefes Arch Clin Exp Ophthalmol. 2025. PMID: 39934352
-
Comprehensive evaluation of intravitreal conbercept versus half-dose photodynamic therapy for chronic central serous chorioretinopathy.Int J Ophthalmol. 2021 May 18;14(5):719-724. doi: 10.18240/ijo.2021.05.12. eCollection 2021. Int J Ophthalmol. 2021. PMID: 34012887 Free PMC article.
-
Photodynamic therapy: current role in the treatment of chorioretinal conditions.Eye (Lond). 2016 Feb;30(2):202-10. doi: 10.1038/eye.2015.251. Epub 2016 Jan 8. Eye (Lond). 2016. PMID: 26742867 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources